Stephen Jackson (scientist)
| Stephen Jackson | |
|---|---|
| Born | July 17, 1962 |
| Fields |
Cancer DNA repair Cell biology Molecular biology |
| Institutions |
Gurdon Institute University of Cambridge University of California, Berkeley University of Edinburgh |
| Alma mater |
University of Leeds (BSc) Imperial College London (PhD) University of Edinburgh (PhD) |
| Thesis | Cloning and characterisation of the RNA8 gene of Saccharomyces cerevisiae (1987) |
| Doctoral advisor | Jean Beggs |
| Known for | Understanding cellular responses to DNA damage and their relevance to cancer |
| Notable awards |
EMBO member (1997) Fellow of the Royal Society (2008) FMedSci (2001) Buchanan Medal (2011) |
|
Website www www2 | |
Stephen Philip Jackson, FRS, FMedSci, (born 17 July 1962 in Nottingham, England) is the Frederick James Quick Professor of Biology and a Fellow of St. John's College, Cambridge. He is a Senior Group Leader and Head of Cancer Research UK Laboratories at the Gurdon Institute, and an Associate Faculty member at the Wellcome Trust Sanger Institute.[1] He is also part-time Chief Scientific Officer for MISSION Therapeutics Ltd.[2]
Education
Professor Jackson was educated at the University of Leeds, graduating with a Bachelor of Science degree in Biochemistry in 1983.[3] He then carried out his PhD research working with Jean Beggs on yeast RNA splicing at Imperial College London and Edinburgh University, earning his PhD in 1987.[4]
Research
Following his PhD, Jackson carried out postdoctoral research with Robert Tjian at the University of California, Berkeley, where he developed an interest in the regulation of transcription. He returned to the UK in 1991 as a Junior Group Leader at the then Wellcome-CRC Institute, now the Gurdon Institute.
In 1997 Jackson founded KuDOS Pharmaceuticals with the aim of translating knowledge of DNA damage response pathways into new treatments for cancer. KuDOS developed into a fully integrated drug-discovery and drug-development company and was acquired by AstraZeneca in 2005.[5]
In 2011 Jackson founded MISSION Therapeutics[2][6] a firm to develop drugs to improve the management of life-threatening diseases, particularly cancer.
Honours and Awards
Jackson has received various prizes, including the Biochemical Society GlaxoSmithKline Award (2008),[7] the BBSRC Innovator of the Year Award (2009)[8] and the Royal Society Buchanan Medal (2011),[9] the latter in recognition of his "outstanding contributions to understanding DNA repair and DNA damage response signalling pathways". He was elected a member of the European Molecular Biology Organization (EMBO) in 1997, a Fellow of the Academy of Medical Sciences in 2001[10] and a Fellow of the Royal Society in 2008.[11]
References
- ↑ Professor Steve Jackson - Associate Faculty, Wellcome Trust Sanger Institute
- ↑ 2.0 2.1 "Scientific Founders". MISSION Therapeutics.
- ↑ ‘JACKSON, Prof. Stephen Philip’ Who's Who 2014, A & C Black, an imprint of Bloomsbury Publishing plc, 2014; online edn, Oxford University Press, 2013
- ↑ Jackson, Stephen Phillip (1987). "Cloning and characterisation of the RNA8 gene of Saccharomyces cerevisiae" (PhD thesis). University of Edinburgh.
- ↑ "Acquisition Of KuDOS Pharmaceuticals Will Enhance AstraZeneca’s Ability To Generate Novel Cancer Treatments" (press release). AstraZeneca. 23 December 2005.
- ↑ "Steve Jackson". Steve Jackson Laboratory.
- ↑ GlaxoSmithKline Award Lecture
- ↑ Innovator of the Year
- ↑ "Royal Society Buchanan Medal".
- ↑ "The Academy of Medical Sciences | Directory of Fellows".
- ↑ "Jackson; Stephen Philip". The Royal Society. Retrieved 24 August 2014.